ClinicalTrials.gg
Status unknownNCT03327285Updated Oct 1, 2020

C-CAR011 Treatment in Subjects With ALL After HSCT

An interventional study of C-CAR011 in Acute Lymphoblastic Leukemia(ALL), sponsored by Peking University People's Hospital. Status unknown at 1 site in China. Open to participants aged 15 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-10-01.

Sponsored by Peking University People's Hospital · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Sep 2020), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
15 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 232 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in China — 113 open to participants now, 125 under way, 11 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · China.

Planned enrollment
110th of 209
40 · median 45
Started
2018
with 10 others
No phase
25 of 232
15 open now
Registered
39th of 232
by date

Among the 232 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in China, this one is the 110th largest by planned enrollment of the 209 interventional ones that give a count, is one of 11 that started in 2018, is one of 25 with no phase, and was the 39th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 472 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

113 of the 232 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in China are open now. Recruiting first, the newest first:

108 more — sign in →

All 113 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 370 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 95 (26%) set no upper age limit and 258 (70%) stop at 75 or younger; 248 take children under 18; 29 take healthy volunteers.

This study: 15 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in China, or all of them as a file.
02

Study summary

This is a single-center, prospective clinical study evaluating safety and efficacy of C-CAR011 treatment in subjects with ALL after HSCT

Read the detailed description

A study evaluating safety and efficacy of CBM.CD19-targeted chimeric antigen receptor T cells (C-CAR011) treatment in subjects with acute lymphoblastic leukemia(ALL) after hematopoietic stem cell transplantation(HSCT). The amount of cells received:1.0-5.0×10\^6CAR+T cells/kg

03

Conditions studied

  • Acute Lymphoblastic Leukemia(ALL)

Keywords

  • Acute lymphoblastic leukemia
  • Hematopoietic stem cell transplantation
  • Anti-CD19 chimeric antigen receptor T-cell
04

Who can participate

Ages eligible
15 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 15-65 years old, male or female.
  • Volunteered to participate in this study and signed .
  • Meet the two populations above.
  • diagnosed as CD19+B-ALL.
  • 100% T lymphocytes of donor.
  • Treatment without chemotherapy and antibody therapy within 2 weeks prior to C-CAR011 therapy.
  • (LVEF) ≧ 50%, no evidence of pericardial effusion and arrhythmias.
  • Baseline oxygen saturation ≧ 92% on room air and with normal pulmonary function, no evidence of active lung infection.
  • Expected survival ≧ 3 months.
  • (ECOG) performance status of 0 or 1.

Exclusion criteria

Exclusion Criteria:

  • History of allergy to cellular products.
  • Any kind of these laboratory testing: serum total ≧2.0mg/dl, serum albumin\<35g/L, , AST≧3×, serum creatinine≧2.0mg/ dl,\<20×109/L.
  • The subjects had active aGVHD with II-IV degrees (Glucksberg degrees) or active moderate to severe cGVHD.
  • Severe uncontrolled infection (mycotic, bacterial, virus and so on).
  • Any central nervous system leukemia(CNS2, CNS3) , with insensitive to intrathecal injection of or radiotherapy of head/spine; but effectively controlled cases will be eligible.
  • The subjects were treated CART cells or DLI after .
  • Bone marrow failure syndrome(BMF) after allogeneic hematopoietic stem cell transplantation.
  • Any genetically modified T cell therapy.
  • History of heavy drinking, drug taking or mental disease.
  • Participated in any other clinical trial within one month prior to enrollment.
  • Women who are pregnant or lactating or have breeding intent in 6 months.
  • The investigators believe that any increase in the risk of the subject or interference with the results of the trial.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    C-CAR011

    The amount of cells received:1.0-5.0×10\^6 CAR+T cells/kg

    Biological: C-CAR011

Interventions

06

What researchers measure

Primary outcomes

  1. TEAEs

    TEAEs evaluated after C-CAR011 infusion

    Time frame: 2 months

  2. GVHD

    GVHD evaluated after C-CAR011 infusion

    Time frame: 2 months

Secondary outcomes

  1. Recurrence rate

    Recurrence rate

    Time frame: 6 and 12 months

  2. OS

    Overall survival (OS) after C-CAR011 infusion

    Time frame: 12 months

  3. PFS

    Progression free survival(PFS)after C-CAR011 infusion

    Time frame: 12 months

  4. Remission rate

    MRD negative after C-CAR011 infusion

    Time frame: 2 weeks to 3 months

07

Study locations

1 site
  • Peking University Institute of Hematology
    Beijing, Beijing 100044, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2018 (actual). Primary completion is estimated for Feb 2021, 35 months after the start.

Of 207 non-industry interventional studies with no phase under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 66. This study's planned 35 months is close to that.

Counting every sponsor, half of 214 studies reached it within 32 months; a quarter within 12 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2017
First posted
Oct 31, 2017
StartActual
Mar 1, 2018
Primary completionEst.
Feb 28, 2021
CompletionEst.
Apr 30, 2021
Last update
Oct 1, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03327285
Responsible party
Xiaojun Huang,MD (Chair, Peking University People's Hospital) — Principal investigator
First posted
Oct 31, 2017
Start date
Mar 1, 2018
Primary completion
Feb 28, 2021 (estimated)
Completion
Apr 30, 2021 (estimated)
Last update
Oct 1, 2020

Study contacts

Xiaojun Huang
principal investigator · Peking University People's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Autologous Anti-CD19 Chimeric Antigen Receptor T-cells C-CAR011

Start the discussion